Barclays Initiates STRO Overweight
Barclays starts coverage of Sutro Biopharma with overweight rating, citing growth potential. This may impact biotech sector stocks.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.